ArticleEuropean journal of medical research2025
ncRNA-mediated ITGB1 upregulation correlates with poor prognosis and tumor-immune infiltration in gastric cancer.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundGastric cancer (GC) is a highly heterogeneous and complex disease. Recently, integrin β (ITGB) superfamily members have been shown to play crucial roles in the initiation and progression of various human cancers. However, the precise role and molecular mechanisms of ITGB1 in GC are yet to be fully elucidated.
methodsThis bioinformatics and clinical study systematically analyzed the pan-cancer expression patterns and prognostic significance of ITGBs using data from The Cancer Genome Atlas and Genotype-Tissue Expression portals. Multivariate regression analysis was performed to identify key factors influencing GC prognosis. Candidate noncoding RNAs (ncRNAs) potentially regulating ITGB1 expression were identified via expression profiling, coexpression assessment, and survival correlation studies. Furthermore, the associations of ITGB1 and its related long ncRNA MIR99AHG with tumor-infiltrating immune cells, immune cell markers, and immune checkpoint molecules in GC were explored.
resultsCompared with adjacent normal tissues, the ITGB1, ITGB2, ITGB4, ITGB5, and ITGB8 mRNA levels were significantly upregulated in GC tissues (p < 0.05). Cox regression and Kaplan-Meier survival analyses indicated that ITGB1 upregulation was associated with poor prognosis (univariable hazards ratio = 1.40, 95% confidence interval 1.008-1.956, p = 0.045) and served as an independent prognostic factor (multivariate hazards ratio = 1.46, 95% confidence interval 1.004-2.140, p = 0.048) in patients with GC. The MIR99AHG/hsa-mir-17-5p axis (r = - 0.56, p < 0.001) was identified as the most promising upstream ncRNA-related pathway regulating ITGB1 expression in GC. In addition, ITGB1 expression in GC and adjacent nontumorous tissues was validated using immunohistochemistry (H-score: 35.4 ± 19.2 vs. 28.4 ± 16.2, respectively; p = 0.035). MIR99AHG expression was similarly assessed through in situ hybridization (H-score: 32.4 ± 15.6 vs. 20.5 ± 11.0, respectively; p < 0.001). There was a positive correlation between ITGB1 expression and infiltrating CD4 + T cells (r = 0.17, p < 0.001), M2 macrophages (r = 0.37, p < 0.001), dendritic cells (r = 0.19, p < 0.001), and immune checkpoints (PD-L1, CTLA-4, and CD28). Particularly, high macrophage infiltration was associated with favorable prognosis in GC (p = 0.004).
conclusionsOur findings suggest that ncRNA-mediated ITGB1 expression is associated with poor prognosis and tumor-immune infiltration in GC. However, further validation through extensive mechanistic studies and large-scale clinical trials is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.